In this article we will discuss Anlotinib (Background-7). So, let’s get started.
Anlotinib (1-[[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-
methoxyquinolin-7-yl]oxy] methyl]cyclopropanamine dihy-
drochloride) is a newly developed oral small-molecule RTKn inhibitor that targets VEGFR1, VEGFR2/KDR, VEGFR3,
c-Kit, PDGFR-α, and the fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). Further, it can inhibit both tumor angiogenesis and tumor cell proliferation. Anlotinib can inhibit more targets than other RTK inhibitors can, including sorafenib, sunitinib, and pazopanib. The various targets of anlotinib and other RTK inhibitors are summarized in Table 1. Anlotinib was developed by Chia-tai Tianqing Pharmaceutical Co., Ltd. in China.